Physician profile
Daniela Meshkat
NPI 1457366205
$4,121.16
in general payments reported to CMS, 2019-2025
29 companies · $611 in 2025
The $611 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $229 · 2021: $242 · 2022: $648 · 2023: $1,464 · 2024: $416 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328 · Consulting Fee: $975 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.10 |
| Consulting Fee | $975.00 |
| Education | $188.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $975.00 | 2023 | |
| Abbvie INC. | $619.21 | 2019-2024 | |
| Hologic Sales and Service, LLC | $443.66 | 2022-2025 | Acessa Provu System, Aptima, Fetal Fibronectin Enzyme Immunoassay |
| Mayne Pharma Commercial LLC | $310.57 | 2022-2025 | |
| Intuitive Surgical, INC. | $300.81 | 2019-2024 | |
| Fisher Scientific Company L.L.C. | $188.48 | 2025 | Procalcitonin |
| Bayer Healthcare Pharmaceuticals INC. | $165.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $112.69 | 2019 | |
| Axonics, INC. | $110.41 | 2022 | |
| Myovant Sciences INC. | $92.12 | 2022 | |
| Aspira Women'S Health INC | $88.11 | 2021-2024 | Ova1 |
| Daiichi Sankyo INC. | $85.63 | 2020-2024 | Injectafer |
| Astellas Pharma US INC | $71.80 | 2023-2024 | Veozah |
| Becton, Dickinson and Company | $65.52 | 2022-2023 | Bd Onclarity |
| Sumitomo Pharma America, INC. | $60.69 | 2023 | Myfembree |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $54.87 | 2022 | |
| Ethicon US, LLC | $50.47 | 2019-2023 | Stratafix |
| Allergan, INC. | $46.41 | 2019 | |
| Therapeuticsmd, INC. | $36.09 | 2020-2022 | |
| Minerva Surgical, INC | $35.22 | 2019-2020 | |
| Gilead Sciences, INC. | $31.20 | 2025 | |
| Pfizer INC. | $29.99 | 2024 | |
| Merck Sharp & Dohme LLC | $29.30 | 2019-2020 | |
| Millicent US INC | $24.15 | 2024 | Femring, Intrarosa |
| Biogen, INC. | $22.30 | 2024 | Zurzuvae |
| Evofem Biosciences, INC. | $21.04 | 2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $20.35 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $15.39 | 2019 | |
| Avion Pharmaceuticals | $14.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Meshkat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.